Neuberger Berman Group LLC Increases Stake in Amgen, Inc. (AMGN)
Neuberger Berman Group LLC lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 1.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 199,886 shares of the medical research company’s stock after acquiring an additional 3,752 shares during the quarter. Neuberger Berman Group LLC’s holdings in Amgen were worth $37,269,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in AMGN. Janus Henderson Group PLC raised its position in shares of Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares in the last quarter. FMR LLC raised its position in shares of Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Renaissance Technologies LLC increased its position in Amgen by 40.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after buying an additional 986,700 shares in the last quarter. BlackRock Inc. increased its position in Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares in the last quarter. 78.59% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on the company. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Mizuho set a $192.00 price objective on Amgen and gave the company a “buy” rating in a research report on Friday, December 22nd. Morgan Stanley reduced their price objective on Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a research report on Friday, February 2nd. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Royal Bank of Canada reduced their price objective on Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $191.49.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $173.46 on Friday. The company has a market capitalization of $126,160.00, a price-to-earnings ratio of 67.23, a price-to-earnings-growth ratio of 2.13 and a beta of 1.42. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.89 EPS. sell-side analysts expect that Amgen, Inc. will post 13.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a $1.32 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.04%. Amgen’s dividend payout ratio (DPR) is presently 178.29%.
Amgen declared that its board has initiated a share buyback program on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/neuberger-berman-group-llc-increases-stake-in-amgen-inc-amgn/1856899.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.